No licensed vaccine is yet available, but the team lead by Prof Reyes-Sandoval has developed a Chikungunya vaccine using the adenovirus ChAdOx1 expressing Virus-Like Particles that elicit immune responses able to produce high antibody titres able to neutralise the virus.
Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus
11 April 2019
Chikungunya virus (CHIKV) has caused explosive outbreaks in more than 60 countries. Infection can cause a long-term, debilitating disease characterised by joint inflammation and chronic arthritis lasting several years.